cabotegravir

The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that it is strongly encouraged by new study results showing that the antiretroviral medicine cabotegravir, which is administered by injection every two months, prevents HIV among women. The study shows that the long-acting injections among women in sub-Saharan Africa were 89% more efficient in preventing HIV compared to daily tablets of pre-exposure prophylaxis (PrEP). “These results are hugely significant. UNAIDS has long been calling for additional, acceptable and effective HIV prevention options